Abstract
The genome-wide DNA methylation status in metastatic colorectal cancer (mCRC) has been reported to be associated with therapeutic sensitivity to anti-epidermal growth factor receptor (EGFR) inhibitors. We recently developed a DNA methylation assay focused on 16 CpG sites that reflect genome-wide DNA methylation status for mCRC based on the modified MethyLight and reported its ability to predict the clinical outcomes of anti-EGFR inhibitors (Ouchi et al. Cancer Sci 2022). Here, we report the predictive performance of a modified MethyLight assay on sensitivity to anti-EGFR inhibitors focused on salvage-line treatment.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call